Sohn, Il Suk; Kim, Chong-Jin; Oh, Byung-Hee; Hong, Taek-Jong; Park, Chang-Gyu; Kim, Byung-Soo; Chung, Woo-Baek
American journal of cardiovascular drugs : drugs, devices, and other interventions
2016Apr ; 16 ( 2 ) :129-38.
PMID : 26691333
ÀúÀÚ »ó¼¼Á¤º¸
Sohn, Il Suk - Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Kim, Chong-Jin - Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Oh, Byung-Hee - Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro(28 Yongon-dong), Jongno-gu, Seoul, 110-744, Republic of Korea. ohbhmed@snu.ac.kr.
Hong, Taek-Jong - Pusan National University Hospital, Busan, Republic of Korea.
Park, Chang-Gyu - Korea University Guro Hospital, Seoul, Republic of Korea.
Kim, Byung-Soo - Daedong Hospital, Busan, Republic of Korea.
Chung, Woo-Baek - Yeouido St. Mary's Hospital of the Catholic University of Korea, Seoul, Republic of Korea. CN - Investigators
ABSTRACT
BACKGROUND: This study was to evaluate the efficacy and safety of triple fixed-dose combination (FDC) therapy with olmesartan medoxomil (OM) 20 mg, amlodipine (AML) 5 mg, and hydrochlorothiazide (HCTZ) 12.5 mg (OM/AML/HCTZ 20/5/12.5) in Korean patients with moderate hypertension not controlled with dual FDC therapy (OM/HCTZ 20/12.5).
METHODS: In this multicenter, randomized, double-blind, parallel-group study, Korean patients aged 20 to 75 years with stage 2 hypertension who had a mean seated diastolic blood pressure (msDBP) ??00 mmHg were enrolled when their BP was uncontrolled [mean seated systolic BP (msSBP)/msDBP >140/90 mmHg or msSBP/msDBP >130/80 mmHg with diabetes or chronic kidney disease] with 4-week dual FDC therapy (OM/HCTZ 20/12.5). The patients were randomized to receive either OM/AML/HCTZ 20/5/12.5 or OM/HCTZ 20/12.5 once daily for 8 weeks. At the end of 8 weeks, patients with uncontrolled BP were assigned to receive either OM/AML/HCTZ 40/5/12.5 or OM/AML/HCTZ 20/5/12.5 in an additional 8-week open-label extension period.
RESULTS: A total of 623 patients received a 4-week run-in treatment with OM/HCTZ, 341 patients were randomized, and finally, 167 patients in the OM/AML/HCTZ group and 171 patients in the OM/HCTZ group were analyzed for the full analysis set. Non-responders after the 8 weeks of double-blind treatment continued the 8-week open-label treatment with OM/AML/HCTZ 40/5/12.5 mg (n = 32) or OM/AML/HCTZ 20/5/12.5 mg (n = 71). After 8 weeks of double-blind treatment, the changes in msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ group and -4.23 (7.41) mmHg in the OM/HCTZ group (both p < 0.0001 vs. baseline; p < 0.0001 between groups). The response rates for both msSBP and msDBP at week 8 were 65.27 % in the OM/AML/HCTZ group and 37.43 % in the OM/HCTZ group (p < 0.0001 between groups). The response rates for both msSBP and msDBP at week 16 after open-label treatment were 18.75 % in the OM/AML/HCTZ 40/5/12.5 group and 46.48 % in the OM/AML/HCTZ 20/5/12.5 group (p = 0.0073 between groups). All medications were well tolerated. CONCLUSION: In Korean patients with moderate hypertension not controlled with dual FDC therapy (OM/HCTZ 20/12.5) as first-line therapy, switching to triple FDC therapy (OM/AML/HCTZ 20/5/12.5) was associated with significant BP reductions and greater achievement of BP goals, and was well tolerated (ClinicalTrials.gov Identifier: NCT01838850).
na
¸µÅ©